BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chacón-Solano E, León C, Díaz F, García-García F, García M, Escámez MJ, Guerrero-Aspizua S, Conti CJ, Mencía Á, Martínez-Santamaría L, Llames S, Pévida M, Carbonell-Caballero J, Puig-Butillé JA, Maseda R, Puig S, de Lucas R, Baselga E, Larcher F, Dopazo J, Del Río M. Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses. Br J Dermatol 2019;181:512-22. [PMID: 30693469 DOI: 10.1111/bjd.17698] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Akasaka E, Nakano H, Sawamura D. Kindler epidermolysis bullosa associated with oral cancer in the buccal mucosa. JAAD Case Rep 2022;26:13-6. [PMID: 35815233 DOI: 10.1016/j.jdcr.2022.06.005] [Reference Citation Analysis]
2 Chen M, Liu Y, Yang Y, Qiu Y, Wang Z, Li X, Zhang W. Emerging roles of activating transcription factor (ATF) family members in tumourigenesis and immunity: Implications in cancer immunotherapy. Genes Dis 2022;9:981-99. [PMID: 35685455 DOI: 10.1016/j.gendis.2021.04.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
3 Chacón-Solano E, León C, Carretero M, García M, Sánchez-Domínguez R, Quero F, Méndez-Jiménez E, Bonafont J, Ruiz-Mezcua B, Escámez MJ, Larcher F, Del Río M. Mechanistic interrogation of mutation-independent disease modulators of RDEB identifies the small leucine-rich proteoglycan PRELP as a TGF-β antagonist and inhibitor of fibrosis. Matrix Biol 2022:S0945-053X(22)00087-7. [PMID: 35779740 DOI: 10.1016/j.matbio.2022.06.007] [Reference Citation Analysis]
4 Takaki S, Shimbo T, Ikegami K, Kitayama T, Yamamoto Y, Yamazaki S, Mori S, Tamai K. Generation of a recessive dystrophic epidermolysis bullosa mouse model with patient-derived compound heterozygous mutations. Lab Invest 2022;102:574-580. [DOI: 10.1038/s41374-022-00735-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Webb ER, Dodd G, Bullock E, Muir M, Frame MC, Serrels A, Brunton VG. Loss of the adhesion protein Kindlin-1 stimulates tumor clearance via modulation of Tregs.. [DOI: 10.1101/2022.03.04.483014] [Reference Citation Analysis]
6 Korolenkova M, Poberezhnaya A, Dmitrieva N. Oral microbiome in children with dystrophic recessive epidermolysis bullosa. Stomat 2022;101:46. [DOI: 10.17116/stomat202210101146] [Reference Citation Analysis]
7 Martínez-deMiguel C, Segura-Bedmar I, Chacón-Solano E, Guerrero-Aspizua S. The RareDis corpus: A corpus annotated with rare diseases, their signs and symptoms. J Biomed Inform 2021;125:103961. [PMID: 34879250 DOI: 10.1016/j.jbi.2021.103961] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
8 Nyström A, Bruckner-Tuderman L, Kiritsi D. Dystrophic Epidermolysis Bullosa: Secondary Disease Mechanisms and Disease Modifiers. Front Genet 2021;12:737272. [PMID: 34650598 DOI: 10.3389/fgene.2021.737272] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Ono J, Takai M, Kamei A, Azuma Y, Izuhara K. Pathological Roles and Clinical Usefulness of Periostin in Type 2 Inflammation and Pulmonary Fibrosis. Biomolecules 2021;11:1084. [PMID: 34439751 DOI: 10.3390/biom11081084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Has C, South A, Uitto J. Molecular Therapeutics in Development for Epidermolysis Bullosa: Update 2020. Mol Diagn Ther 2020;24:299-309. [PMID: 32328988 DOI: 10.1007/s40291-020-00466-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 16.5] [Reference Citation Analysis]
11 Rian K, Hidalgo MR, Çubuk C, Falco MM, Loucera C, Esteban-Medina M, Alamo-Alvarez I, Peña-Chilet M, Dopazo J. Genome-scale mechanistic modeling of signaling pathways made easy: A bioconductor/cytoscape/web server framework for the analysis of omic data. Comput Struct Biotechnol J 2021;19:2968-78. [PMID: 34136096 DOI: 10.1016/j.csbj.2021.05.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Tartaglia G, Cao Q, Padron ZM, South AP. Impaired Wound Healing, Fibrosis, and Cancer: The Paradigm of Recessive Dystrophic Epidermolysis Bullosa. Int J Mol Sci 2021;22:5104. [PMID: 34065916 DOI: 10.3390/ijms22105104] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
13 Beilin AK, Evtushenko NA, Lukyanov DK, Murashkin NN, Ambarchian ET, Pushkov AA, Savostyanov KV, Fisenko AP, Rogovaya OS, Vasiliev AV, Vorotelyak EA, Gurskaya NG. Signatures of Dermal Fibroblasts from RDEB Pediatric Patients. Int J Mol Sci 2021;22:1792. [PMID: 33670258 DOI: 10.3390/ijms22041792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Garrido-Rodriguez M, Lopez-Lopez D, Ortuno FM, Peña-Chilet M, Muñoz E, Calzado MA, Dopazo J. A versatile workflow to integrate RNA-seq genomic and transcriptomic data into mechanistic models of signaling pathways. PLoS Comput Biol 2021;17:e1008748. [PMID: 33571195 DOI: 10.1371/journal.pcbi.1008748] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Lincoln V, Chao L, Woodley DT, Murrell D, Kim M, O'Toole EA, Ly A, Cogan J, Mosallaei D, Wysong A, Chen M. Over-expression of stromal periostin correlates with poor prognosis of cutaneous squamous cell carcinomas. Exp Dermatol 2021;30:698-704. [PMID: 33450077 DOI: 10.1111/exd.14281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
16 Rian K, Esteban-Medina M, Hidalgo MR, Çubuk C, Falco MM, Loucera C, Gunyel D, Ostaszewski M, Peña-Chilet M, Dopazo J. Mechanistic modeling of the SARS-CoV-2 disease map. BioData Min 2021;14:5. [PMID: 33478554 DOI: 10.1186/s13040-021-00234-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
17 Nyström A, Kiritsi D, Bruckner-tuderman L. Skin Blistering and Collagens: From Bench to Therapies. The Collagen Superfamily and Collagenopathies 2021. [DOI: 10.1007/978-3-030-67592-9_7] [Reference Citation Analysis]
18 Dopazo J. Molecular Genetics in the Next Generation Sequencing Era. Mitochondrial Diseases 2021. [DOI: 10.1007/978-3-030-70147-5_9] [Reference Citation Analysis]
19 Rami A, Łaczmański Ł, Jacków-Nowicka J, Jacków J. Reprogramming and Differentiation of Cutaneous Squamous Cell Carcinoma Cells in Recessive Dystrophic Epidermolysis Bullosa. Int J Mol Sci 2020;22:E245. [PMID: 33383666 DOI: 10.3390/ijms22010245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Tietzová I, Twaroski K, Eide C, H. Ostrander J, Crawford P, Tolar J. Impaired Mitochondrial and Metabolic Function of Fibroblasts Derived from Patients with Recessive Dystrophic and Junctional Epidermolysis Bullosa. EMJ Dermatol. [DOI: 10.33590/emjdermatol/20-00007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Akasaka E, Kleiser S, Sengle G, Bruckner-Tuderman L, Nyström A. Diversity of Mechanisms Underlying Latent TGF-β Activation in Recessive Dystrophic Epidermolysis Bullosa. J Invest Dermatol 2021;141:1450-1460.e9. [PMID: 33333127 DOI: 10.1016/j.jid.2020.10.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
22 Prodinger C, Bauer JW, Laimer M. Translational perspectives to treat Epidermolysis bullosa-Where do we stand? Exp Dermatol 2020;29:1112-22. [PMID: 33043517 DOI: 10.1111/exd.14194] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
23 Papanikolaou M, Onoufriadis A, Mellerio JE, Nattkemper LA, Yosipovitch G, Steinhoff M, McGrath JA. Prevalence, pathophysiology and management of itch in epidermolysis bullosa. Br J Dermatol 2021;184:816-25. [PMID: 32810291 DOI: 10.1111/bjd.19496] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
24 Maseda R, Martínez-Santamaría L, Sacedón R, Butta N, de Arriba MDC, García-Barcenilla S, García M, Illera N, Pérez-Conde I, Carretero M, Jiménez E, Melen G, Borobia AM, Jiménez-Yuste V, Vicente Á, Del Río M, de Lucas R, Escámez MJ. Beneficial Effect of Systemic Allogeneic Adipose Derived Mesenchymal Cells on the Clinical, Inflammatory and Immunologic Status of a Patient With Recessive Dystrophic Epidermolysis Bullosa: A Case Report. Front Med (Lausanne) 2020;7:576558. [PMID: 33324660 DOI: 10.3389/fmed.2020.576558] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
25 Wally V, Reisenberger M, Kitzmüller S, Laimer M. Small molecule drug development for rare genodermatoses - evaluation of the current status in epidermolysis bullosa. Orphanet J Rare Dis 2020;15:292. [PMID: 33076941 DOI: 10.1186/s13023-020-01467-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
26 Aguado T, García M, García A, Ferrer-Mayorga G, Martínez-Santamaría L, Del Río M, Botella LM, Sánchez-Puelles JM. Raloxifene and n-Acetylcysteine Ameliorate TGF-Signalling in Fibroblasts from Patients with Recessive Dominant Epidermolysis Bullosa. Cells 2020;9:E2108. [PMID: 32947957 DOI: 10.3390/cells9092108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
27 Çubuk C, Can FE, Peña-Chilet M, Dopazo J. Mechanistic Models of Signaling Pathways Reveal the Drug Action Mechanisms behind Gender-Specific Gene Expression for Cancer Treatments. Cells 2020;9:E1579. [PMID: 32610626 DOI: 10.3390/cells9071579] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
28 Falco MM, Peña-Chilet M, Loucera C, Hidalgo MR, Dopazo J. Mechanistic models of signaling pathways deconvolute the glioblastoma single-cell functional landscape. NAR Cancer 2020;2:zcaa011. [PMID: 34316686 DOI: 10.1093/narcan/zcaa011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
29 Guerrero-Aspizua S, González-Masa A, Conti CJ, García M, Chacón-Solano E, Larcher F, Del Río M. Humanization of Tumor Stroma by Tissue Engineering as a Tool to Improve Squamous Cell Carcinoma Xenograft. Int J Mol Sci 2020;21:E1951. [PMID: 32178458 DOI: 10.3390/ijms21061951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
30 Bellei B, Caputo S, Carbone A, Silipo V, Papaccio F, Picardo M, Eibenschutz L. The Role of Dermal Fibroblasts in Nevoid Basal Cell Carcinoma Syndrome Patients: An Overview. Int J Mol Sci 2020;21:E720. [PMID: 31979112 DOI: 10.3390/ijms21030720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Peña-Chilet M, Esteban-Medina M, Falco MM, Rian K, Hidalgo MR, Loucera C, Dopazo J. Using mechanistic models for the clinical interpretation of complex genomic variation. Sci Rep 2019;9:18937. [PMID: 31831811 DOI: 10.1038/s41598-019-55454-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
32 Falco MM, Peña-chilet M, Loucera C, Hidalgo MR, Dopazo J. Mechanistic models of signaling pathways deconvolute the functional landscape of glioblastoma at single cell resolution.. [DOI: 10.1101/858811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Condorelli AG, Dellambra E, Logli E, Zambruno G, Castiglia D. Epidermolysis Bullosa-Associated Squamous Cell Carcinoma: From Pathogenesis to Therapeutic Perspectives. Int J Mol Sci 2019;20:E5707. [PMID: 31739489 DOI: 10.3390/ijms20225707] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 11.8] [Reference Citation Analysis]
34 Guerrero-Aspizua S, Conti CJ, Escamez MJ, Castiglia D, Zambruno G, Youssefian L, Vahidnezhad H, Requena L, Itin P, Tadini G, Yordanova I, Martin L, Uitto J, Has C, Del Rio M. Assessment of the risk and characterization of non-melanoma skin cancer in Kindler syndrome: study of a series of 91 patients. Orphanet J Rare Dis 2019;14:183. [PMID: 31340837 DOI: 10.1186/s13023-019-1158-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
35 Esteban-Medina M, Peña-Chilet M, Loucera C, Dopazo J. Exploring the druggable space around the Fanconi anemia pathway using machine learning and mechanistic models. BMC Bioinformatics 2019;20:370. [PMID: 31266445 DOI: 10.1186/s12859-019-2969-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
36 Has C. Chronic tissue damage: a common pathomechanism of genodermatoses. Br J Dermatol 2019;181:440-1. [DOI: 10.1111/bjd.18104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Esteban M, Peña-chilet M, Loucera C, Dopazo J. Exploring the druggable space around the Fanconi anemia pathway using machine learning and mechanistic models.. [DOI: 10.1101/647735] [Reference Citation Analysis]